Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to Rhyd6,eyeball08,Wondergirly,bofh,johnstevens77, for Donating to support the site

GlaxoSmithKline PLC (GSK) - 1st Quarter Results

For discussion of the practicalities of setting up and operating income-portfolios which follow the HYP Group Guidelines. READ Guidelines before posting
Forum rules
Tight HYP discussions only please - OT please discuss in strategies
IanTHughes
Lemon Quarter
Posts: 1790
Joined: May 2nd, 2018, 12:01 pm
Has thanked: 730 times
Been thanked: 1117 times

GlaxoSmithKline PLC (GSK) - 1st Quarter Results

#218702

Postby IanTHughes » May 1st, 2019, 12:49 pm

Can be found here:

https://www.investegate.co.uk/glaxosmit ... LC%20Alert

Financial highlights

· Pharmaceuticals sales £4.2 billion, +4% AER, +2% CER; Vaccines £1.5 billion, +23% AER, +20% CER; Consumer Healthcare £2.0 billion, flat AER, +1% CER.
· Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER (Pharmaceuticals 29.8%; Vaccines 40.3%; Consumer Healthcare 21.7%). Benefits from strong sales growth and phasing of R&D.
· Total EPS 16.8p, +50% AER, +42% CER.
· Adjusted EPS 30.1p, +22% AER, +18% CER, driven by strong operating performance, continued financial efficiencies, reduction in minority share and a one-off benefit to associates.
· Net cash flow from operations £663 million. Free cash flow £165 million.
· 19p dividend declared for the quarter; continue to expect 80p for full year 2019.
· 2019 Guidance reaffirmed.


Returns to shareholders

Quarterly dividends
The Board has declared a first interim dividend for 2019 of 19 pence per share (Q1 2018: 19 pence per share).

GSK recognises the importance of dividends to shareholders and aims to distribute regular dividend payments that will be determined primarily with reference to the free cash flow generated by the business after funding the investment necessary to support the Group's future growth.

The Board intends to maintain the dividend for 2019 at the current level of 80p per share, subject to any material change in the external environment or performance expectations. Over time, as free cash flow strengthens, it intends to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x, before returning the dividend to growth.

Payment of dividends
The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 9 July 2019. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) (2018: $0.02 per ADS; $0.005 per ADS per quarter) is charged by the Depositary.

The ex-dividend date will be 16 May 2019, with a record date of 17 May 2019 and a payment date of 11 July 2019.



Maintaining the dividend at last year's level was of course already advised by the company. Still, it is nice to confirm no cut - for Q1 anyway


Ian

Breelander
Lemon Quarter
Posts: 4179
Joined: November 4th, 2016, 9:42 pm
Has thanked: 1001 times
Been thanked: 1855 times

Re: GlaxoSmithKline PLC (GSK) - 1st Quarter Results

#218765

Postby Breelander » May 1st, 2019, 5:09 pm

IanTHughes wrote:Maintaining the dividend at last year's level was of course already advised by the company. Still, it is nice to confirm no cut - for Q1 anyway


It's a fairly safe bet that Q2/3/4 are going to repeat the 19/19/23p that GSK have paid since 2014 - barring a 'black swan event', that is...

(Disc: holding GSK since 2010)


Return to “HYP Practical (See Group Guidelines)”

Who is online

Users browsing this forum: No registered users and 19 guests